Journey Medical Corporation (NASDAQ:DERM) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Interim Chief Financial Officer Dr. Srinivas Sidgiddi - Vice President, Research and Development Ramsey Allous - General Counsel and Corporate Secretary Conference Call Participants Scott Henry - ROTH Capital Andy Fleszar - B. Riley Operator Ladies and gentlemen, thank y ...

Journey Medical Corporation (NASDAQ:DERM) Q2 2023 Earnings Conference Call August 8, 2023 4:00 PM ET Company Participants Matt Blazei - CoreIR Claude Maraoui - Co-Founder, President and Chief Executive Officer Joseph Benesch - Interim Chief Financial Officer Srinivas Sidgiddi - Vice President of R&D Neal Bhatia - Director of Clinical Dermatology at Therapeutics Clinical Research Conference Call Participants Scott Henry - Roth capital Kalpit Patel - B. Riley Securities Operator Ladies and Gentleman, thank yo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-41063 JOURNEY MEDICAL CORPORATION (Exact name of registrant as specified in its charter) ( ...

Journey Medical Corp (NASDAQ:DERM) Q1 2023 Earnings Conference Call May 22, 2023 4:30 PM ET Company Participants Matt Blazei - CORE IR Claude Maraoui - Founder, President and CEO Joseph Benesch - Interim CFO Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Journey Medical's First Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode. [Operator Instructions] Participan ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-41063 JOURNEY MEDICAL CORPORATION (Exact name of registrant as specified in its charter) ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or JOURNEY MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 47-1879539 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 9237 E Via de Ventura Blvd., Suite 105 Scottsdale, AZ 85258 (Address of Pri ...

Journey Medical Corp (NASDAQ:DERM) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Matt Blazei - CORE IR Claude Maraoui - Founder, President, CEO & Director Joseph Benesch - Interim CFO Srinivas Sidgiddi - VP, Clinical Development & Medical Affairs Conference Call Participants Brandon Folkes - Cantor Fitzgerald Scott Henry - ROTH MKM Partners Andrew Fleszar - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the Jour ...

Journey Medical Corporation (NASDAQ:DERM) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Blazei – CORE IR Claude Maraoui – Co-Founder, President and Chief Executive Officer Ernie De Paolantonio – Chief Financial Officer Ramsey Alloush – General Counsel Conference Call Participants Scott Henry – ROTH Capital Brandon Folkes – Cantor Fitzgerald Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the Journey Medical’s Third Quarter 20 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-41063 JOURNEY MEDICAL CORPORATION (Exact name of registrant as specified in its chart ...

Journey Medical Corporation (NASDAQ:DERM) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Claude Maraoui - Co-Founder President and Chief Executive Officer Ernest De Paolantonio - Chief Financial Officer Ramsey Alloush - General Counsel Dr. Srinivas Sidgiddi - Vice President of Clinical Development and Medical Affairs Jules Abraham - IR, CORE IR Conference Call Participants Brandon Folkes - Cantor Fitzgerald Mayank Mamtani - B. Riley FBR Operator Ladies and gentlemen, thank yo ...